Moderna’s cancer vaccine is ‘likely’ to get approved. Skeptics question if it will be the best option.
The first Phase 3 data for a custom cancer vaccine has raised questions about whether the potential new treatment is needed.
The first Phase 3 data for a custom cancer vaccine has raised questions about whether the potential new treatment is needed. This story matters for Finance & Markets readers tracking option. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. OptionNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily option signal